195 related articles for article (PubMed ID: 12176876)
1. Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia.
Kantarjian HM; O'Brien S; Cortes JE; Giralt SA; Rios MB; Shan J; Giles FJ; Thomas DA; Faderl S; De Lima M; Garcia-Manero G; Champlin R; Arlinghaus R; Talpaz M
Blood; 2002 Sep; 100(5):1590-5. PubMed ID: 12176876
[TBL] [Abstract][Full Text] [Related]
2. Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease.
DeAngelo DJ; Hochberg EP; Alyea EP; Longtine J; Lee S; Galinsky I; Parekkedon B; Ritz J; Antin JH; Stone RM; Soiffer RJ
Clin Cancer Res; 2004 Aug; 10(15):5065-71. PubMed ID: 15297408
[TBL] [Abstract][Full Text] [Related]
3. Imatinib combined with myeloablative allogeneic hematopoietic stem cell transplantation for advanced phases of chronic myeloid leukemia.
Luo Y; Zhao Y; Tan Y; Shi J; Han X; Zheng Y; Li L; He J; Xie W; Ye X; Cai Z; Lin M; Huang H
Leuk Res; 2011 Oct; 35(10):1307-11. PubMed ID: 21354617
[TBL] [Abstract][Full Text] [Related]
4. Sustained cytogenetic remission induced by imatinib mesylate in a chronic myeloid leukemia patient who had a relapse into lymphoid crisis after allogeneic hematopoietic stem cell transplantation.
Yujiri T; Sato Y; Tanizawa Y
Int J Hematol; 2004 Jul; 80(1):67-9. PubMed ID: 15293571
[TBL] [Abstract][Full Text] [Related]
5. Allogeneic stem-cell transplantation provides excellent results in advanced stage chronic myeloid leukemia with major cytogenetic response to pre-transplant imatinib therapy.
Weisser M; Schleuning M; Haferlach C; Schwerdtfeger R; Kolb HJ
Leuk Lymphoma; 2007 Feb; 48(2):295-301. PubMed ID: 17325889
[TBL] [Abstract][Full Text] [Related]
6. Current results on the use of imatinib mesylate in patients with relapsed Philadelphia chromosome positive leukemia after allogeneic or syngeneic hematopoietic stem cell transplantation.
Ullmann AJ; Hess G; Kolbe K; Friedrich-Freksa A; Meyer RG; Gschaidmeier H; Huber C; Fischer T
Keio J Med; 2003 Sep; 52(3):182-8. PubMed ID: 14529151
[TBL] [Abstract][Full Text] [Related]
7. Central nervous system relapse in two patients with chronic myelogenous leukemia in myeloid blastic phase on imatinib mesylate therapy.
Rytting ME; Wierda WG
Leuk Lymphoma; 2004 Aug; 45(8):1623-6. PubMed ID: 15370215
[TBL] [Abstract][Full Text] [Related]
8. U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval.
Cohen MH; Johnson JR; Pazdur R
Clin Cancer Res; 2005 Jan; 11(1):12-9. PubMed ID: 15671523
[TBL] [Abstract][Full Text] [Related]
9. Hematopathologic and cytogenetic findings in imatinib mesylate-treated chronic myelogenous leukemia patients: 14 months' experience.
Braziel RM; Launder TM; Druker BJ; Olson SB; Magenis RE; Mauro MJ; Sawyers CL; Paquette RL; O'Dwyer ME
Blood; 2002 Jul; 100(2):435-41. PubMed ID: 12091333
[TBL] [Abstract][Full Text] [Related]
10. Imatinib mesylate (STI571) in the treatment of relapse of chronic myeloid leukemia after allogeneic stem cell transplantation.
Olavarria E; Craddock C; Dazzi F; Marin D; Marktel S; Apperley JF; Goldman JM
Blood; 2002 May; 99(10):3861-2. PubMed ID: 11986250
[TBL] [Abstract][Full Text] [Related]
11. Cytogenetic clonal evolution alone in CML relapse post-transplantation does not adversely affect response to imatinib mesylate treatment.
Kim YJ; Kim DW; Lee S; Kim YL; Hwang JY; Park YH; Kim HJ; Lee JW; Min WS; Kim CC
Bone Marrow Transplant; 2004 Jan; 33(2):237-42. PubMed ID: 14628081
[TBL] [Abstract][Full Text] [Related]
12. Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
Cortes J; Talpaz M; O'Brien S; Giles F; Beth Rios M; Shan J; Faderl S; Garcia-Manero G; Ferrajoli A; Wierda W; Kantarjian H
Cancer; 2003 Sep; 98(6):1105-13. PubMed ID: 12973833
[TBL] [Abstract][Full Text] [Related]
13. Imatinib mesylate (STI571) in preparation for allogeneic hematopoietic stem cell transplantation and donor lymphocyte infusions in patients with Philadelphia-positive acute leukemias.
Shimoni A; Kröger N; Zander AR; Rowe JM; Hardan I; Avigdor A; Yeshurun M; Ben-Bassat I; Nagler A
Leukemia; 2003 Feb; 17(2):290-7. PubMed ID: 12592325
[TBL] [Abstract][Full Text] [Related]
14. Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure.
Jabbour E; Cortes J; Kantarjian HM; Giralt S; Jones D; Jones R; Giles F; Andersson BS; Champlin R; de Lima M
Blood; 2006 Aug; 108(4):1421-3. PubMed ID: 16601247
[TBL] [Abstract][Full Text] [Related]
15. Molecular response to imatinib mesylate following relapse after allogeneic SCT for CML.
McCann SR; Gately K; Conneally E; Lawler M
Blood; 2003 Feb; 101(3):1200-1. PubMed ID: 12529295
[No Abstract] [Full Text] [Related]
16. Imatinib synergizes with donor lymphocyte infusions to achieve rapid molecular remission of CML relapsing after allogeneic stem cell transplantation.
Savani BN; Montero A; Kurlander R; Childs R; Hensel N; Barrett AJ
Bone Marrow Transplant; 2005 Dec; 36(11):1009-15. PubMed ID: 16205732
[TBL] [Abstract][Full Text] [Related]
17. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase.
Kantarjian HM; Cortes J; O'Brien S; Giles FJ; Albitar M; Rios MB; Shan J; Faderl S; Garcia-Manero G; Thomas DA; Resta D; Talpaz M
Blood; 2002 May; 99(10):3547-53. PubMed ID: 11986206
[TBL] [Abstract][Full Text] [Related]
18. Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease.
Posthuma EF; Marijt EW; Barge RM; van Soest RA; Baas IO; Starrenburg CW; van Zelderen-Bhola SL; Fibbe WE; Smit WM; Willemze R; Falkenburg JH
Biol Blood Marrow Transplant; 2004 Mar; 10(3):204-12. PubMed ID: 14993886
[TBL] [Abstract][Full Text] [Related]
19. Second-generation tyrosine kinase inhibitors combined with stem cell transplantation in patients with imatinib-refractory chronic myeloid leukemia.
Zhao Y; Luo Y; Shi J; Cai Z; Huang H
Am J Med Sci; 2014 Jun; 347(6):439-45. PubMed ID: 24553398
[TBL] [Abstract][Full Text] [Related]
20. Imatinib mesylate (STI 571)--a new oral target therapy for chronic myelogenous leukemia (CML).
Chrobák L; Voglová J
Acta Medica (Hradec Kralove); 2003; 46(3):85-9. PubMed ID: 14677715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
